Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584608 · ClinicalTrials.gov registry record · Phase 2
Use of ACTIMMUNE in Patients With ADO2
A Phase 2 study of Autosomal Dominant Osteopetrosis Type 2, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02584608 is a Phase 2 study of Autosomal Dominant Osteopetrosis Type 2 that has completed, run by Indiana University. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02584608, a Phase 2 study of Autosomal Dominant Osteopetrosis Type 2, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.
Conditions Studied
Interventions
- DRUG ACTIMMUNE
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01-01 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584608
The ClinicalTrials.gov registry entry for NCT02584608 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autosomal Dominant Osteopetrosis Type 2 appearing as the primary indexed condition, and to 1 intervention - of which ACTIMMUNE is the first listed.
NCT02584608 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02584608 about?
NCT02584608 is a clinical study titled "Use of ACTIMMUNE in Patients With ADO2". This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospita...
What is the current status of trial NCT02584608?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-01-01. Estimated completion is 2019-11-12.
What conditions does trial NCT02584608 study?
This clinical trial studies the following conditions: Autosomal Dominant Osteopetrosis Type 2.
What interventions are being tested in trial NCT02584608?
The interventions under investigation include: ACTIMMUNE (DRUG).
Who is sponsoring clinical trial NCT02584608?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02584608 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.